ETBF and the Evolution of Obesity: Why we Are prone to becoming 'Fat' ? (Obesity: Ozempic or Olympic size denial?)

Abstract

Modern metabolic disease is classically framed as a behavioral pathology driven by caloric surplus and sedentary lifestyles—an institutional narrative that subtly shifts systemic failure onto the individual. This paper challenges this paradigm by introducing an alternative, highly integrated systems-biology model: an engineered chemical and microbial trap wherein industrial food processing, corporate agribusiness, and systemic clinical over-prescribing act in synergy to weaponize the human gut microbiome [Sears 2009]. Central to this hypothesis is the forced transformation of Bacteroides fragilis from a benign commensal into a hyper-virulent, systemic pathogen [Wexler 2007]. By exploiting the structural features of modern takeout cuisine—specifically 16-carbon palmitate, industrial trans fatty acyls, refined glucose, high-density sodium chloride, chemical emulsifiers, and glyphosate residues—Enterotoxigenic Bacteroides fragilis (ETBF) executes a coordinated, multi-staged deconstruction of the host’s mucosal and epithelial containment fields [Leiva 2021, Wu 2006].

The subsequent fluid-driven, systemic translocation of microbial dipeptidyl peptidase-4 (mDPP4), lipopolysaccharide (LPS) endotoxins, and Bacteroides fragilis toxin (BFT) initiates an unmanageable multi-organ cascade [Kiela 2016, Wu 2006]. This cascade drives localized neuro-inflammation in the hypothalamus, induces profound satiety-receptor blindness, and causes the structural mutilation of insulin at the pancreatic level [Ennis 2026]. This comprehensive molecular cycle completely disables human homeostatic software. It leaves the host in a state of intractable, morbid obesity—a modern evolutionary mismatch that current pharmaceutical blockbusters, such as the DPP-4-resistant GLP-1 receptor agonist semaglutide, merely exploit for commercial capture rather than structurally cure.